Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model

The development of new treatment agents in recent decades has significantly improved the survival of patients with multiple myeloma (MM). Nonetheless, MM remains an incurable disease; therefore, novel combination therapies are required. Natural killer (NK) cells are one of the safest immunotherapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Thangaraj, Jaya Lakshmi, Jung, Sung-Hoon, Vo, Manh-Cuong, Chu, Tan-Huy, Phan, Minh-Trang Thi, Lee, Kyung-Hwa, Ahn, Seo-Yeon, Kim, Mihee, Song, Ga-Young, Ahn, Jae-Sook, Yang, Deok-Hwan, Kim, Hyeoung-Joon, Cho, Duck, Lee, Je-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110729/
https://www.ncbi.nlm.nih.gov/pubmed/36385211
http://dx.doi.org/10.1007/s00262-022-03322-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110729/
https://www.ncbi.nlm.nih.gov/pubmed/36385211
http://dx.doi.org/10.1007/s00262-022-03322-1

Ejemplares similares